One in four seniors with dementia is prescribed the very drugs guidelines warn against

A large study of Medicare records has found that about one in four older adults with dementia is prescribed at least one central nervous system drug that clinical guidelines specifically warn against for that population. The gap between what the guidance says and what actually gets prescribed points to a persistent blind spot in dementia care, one that plays out quietly in doctor’s offices and pharmacies rather than in any single dramatic incident.

What the Medicare-linked research measured

Researchers built the analysis by linking data from a federal health and retirement survey to Medicare claims, allowing them to track prescription patterns for people diagnosed with dementia between 2013 and 2021. Rather than looking at prescribing in isolation, the team focused on five classes of drugs known to act on the central nervous system in ways considered especially risky for older adults already living with cognitive decline, then measured how often those drugs were dispensed without a documented clinical reason that would justify the risk.

The five drug classes at the center of the warning

The medications in question include antipsychotics, barbiturates and benzodiazepines, along with other central-nervous-system-active drugs frequently used to manage anxiety, insomnia, or agitation. Clinical guidelines have long flagged these classes as carrying outsized risks for people with dementia specifically because the drugs are linked to falls, worsened confusion, and hospitalization in a population that is already more vulnerable to each of those outcomes than the general older-adult population. That combination, drugs meant to calm agitation potentially worsening the very cognitive symptoms they are supposed to manage, is what has kept the classes on watch lists for geriatric prescribing for years.

A modest decline that still leaves most prescriptions unexplained

The data does show some improvement over the study period. Prescriptions that researchers judged clinically justified fell only slightly, from about 6 percent of the dementia population in 2013 to roughly 5.5 percent by 2021, while prescriptions the researchers classified as likely inappropriate dropped more meaningfully, from 15.7 percent down to 11.4 percent over the same stretch. Even with that decline, the underlying problem persisted: by the end of the study period, more than two-thirds of patients receiving one of these central-nervous-system-active drugs had no documented clinical indication in their records explaining why the prescription was appropriate for their specific case.

Why documentation gaps matter as much as the prescriptions themselves

The missing paper trail is not just a bureaucratic detail. When a prescription lacks a documented reason tied to a patient’s specific symptoms, it becomes far harder for a subsequent physician, a pharmacist, or a family caregiver to evaluate whether the drug is still necessary, whether the dose should be adjusted, or whether it should be tapered off altogether. Dementia care frequently involves multiple providers and care transitions between home, assisted living, and hospital settings, and a prescription that was started years earlier for a since-forgotten reason can simply keep being renewed by default, carried forward from one care setting to the next without anyone actively re-evaluating it.

How a prescription can outlast its original reason

Part of what makes this pattern so durable is how dementia care typically unfolds over years rather than a single diagnosis appointment. A medication might be started early on to manage a specific, time-limited episode of agitation or insomnia, then simply get renewed at each subsequent visit as a matter of routine rather than active reassessment, especially once a patient’s ability to describe their own symptoms declines alongside their cognition. Over time, the original clinical reasoning behind the prescription can effectively disappear from active memory even though the medication itself keeps being refilled, which helps explain why researchers found so many prescriptions lacking a documented justification years into the study period rather than only at the very start.

What the pattern means for families managing a relative’s medications

For families navigating dementia care, the research underscores the value of periodically reviewing every medication a relative is taking with a physician or pharmacist, rather than assuming that a prescription still in use must still be needed. Because the specific drug classes involved, antipsychotics, barbiturates and benzodiazepines among them, are tied to measurable risks like falls and hospitalization in people with dementia, a conversation about whether a given prescription has a current clinical justification can be a concrete, low-cost step toward reducing that risk. The persistence of this gap across nearly a decade of Medicare data suggests it is not a one-time oversight but a structural pattern in how prescribing decisions get made and, just as often, left unexamined once a patient’s dementia diagnosis is already on the chart.

Why stopping these drugs safely still requires medical guidance

None of this means a family should stop a relative’s medication unilaterally, since several of the drug classes flagged in the research, benzodiazepines in particular, can cause serious withdrawal effects if stopped abruptly after long-term use. The safer path researchers and geriatric specialists generally point to is a gradual, supervised taper conducted with a physician who can watch for withdrawal symptoms and substitute non-drug approaches to managing agitation or anxiety where appropriate. That distinction, between raising the question of whether a prescription is still justified and attempting to remove it without medical support, is central to translating findings like these into safer outcomes rather than a different set of risks.

This article was produced with AI assistance and edited by Morning Overview staff.

More from Morning Overview